Analyst Ratings for Amylin Pharmaceuticals (AMLN) [Sells]
AMLN Rating Summary
AMLN Price Target Summary
- Highest: $32.00 (Jefferies)
- Lowest: $8.00 (Rodman & Renshaw)
- Average: $18.50
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$18.50 (-40.3%)
Avg. $ Target:
$18.50 (-40.3%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/26/2012 | Canaccord Genuity | New Coverage | Sell (N/A) |
12.00 (N/A) |
15.52 | 30.98 | 99.61% | Details |
| 1/5/2012 | Rodman & Renshaw | New Coverage | Market Underperform (N/A) |
8.00 (N/A) |
11.17 | 30.98 | 177.35% | Details |
| 3/3/2011 | Hapoalim Securities | Downgrade | Sell (N/A) |
N/A (N/A) |
11.35 | 30.98 | 172.95% | Details |
| 2/8/2011 | Goldman Sachs » Updated 1/30/2012 |
New Coverage | Sell (N/A) |
11.00 (N/A) |
16.07 | 30.98 | 92.78% | Details |
